597562-79-3

Basic information

• Product Name: 1,2,3,4-TETRAHYDRO-QUINOLINE-7-CARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE
• Synonyms: 1,2,3,4-TETRAHYDRO-QUINOLINE-7-CARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE;1,2,3,4-Tetrahydro-quinoline-7-carboxylicacidmet;Methyl 1,2,3,4-tetrahydroquinoline-7-carboxylate hydrochloride;1,2,3,4-Tetrahydro-quinoline-7-carboxylic acid methyl ester;7-Quinolinecarboxylic acid, 1,2,3,4-tetrahydro-, methyl ester
• CAS NO: 597562-79-3
• Molecular Formula: C₁₁H₁₃NO₂
• Molecular Weight: 227.68736
• Mol File: 597562-79-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,2,3,4-TETRAHYDRO-QUINOLINE-7-CARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4-TETRAHYDRO-QUINOLINE-7-CARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE(597562-79-3)
• EPA Substance Registry System: 1,2,3,4-TETRAHYDRO-QUINOLINE-7-CARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE(597562-79-3)

Safety Data

• Hazardous Substances Data: 597562-79-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1,2,3,4-TETRAHYDRO-QUINOLINE-7-CARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE is used as a key intermediate in the synthesis of various drugs and pharmaceutical products for its potential biological activities and role in drug development.
Used in Medicinal Chemistry:
1,2,3,4-TETRAHYDRO-QUINOLINE-7-CARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE is used as a building block in organic synthesis for the development of new compounds with potential therapeutic applications, contributing to the advancement of drug discovery.
Used in Chemical Research:
1,2,3,4-TETRAHYDRO-QUINOLINE-7-CARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE is used as a research compound to study its properties and potential applications in various chemical processes and reactions, aiding in the understanding of its role in chemical and biological systems.

InChI:InChI=1/C11H13NO2.ClH/c1-14-11(13)9-5-4-8-3-2-6-12-10(8)7-9;/h4-5,7,12H,2-3,6H2,1H3;1H

Upstream product

• 64-17-5 ethanol 
• 51552-68-2 quinoline-7-carboxylic acid methyl ester 

Downstream Products

• 1034776-74-3 1-(2-methoxy-5-methyl-benzenesulfonyl)-1,2,3,4-tetrahydro-quinoline-7-carboxylic acid methyl ester 
• 1030846-96-8 methyl 1-phenyl-1,2,3,4-tetrahydroquinoline-7-carboxylate 
• 1030847-11-0 (1-phenyl-1,2,3,4-tetrahydroquinolin-7-yl)methanol 
• 1034775-95-5 (4-{[1-(2-methoxy-5-methyl-benzenesulfonyl)-1,2,3,4-tetrahydro-quinoline-7-carbonyl]-amino}-phenyl)-acetic acid 

Relevant articles and documents

Ni0/Niδ+ Synergistic Catalysis on a Nanosized Ni Surface for Simultaneous Formation of C-C and C-N Bonds

Simultaneous formation of C-C/C-N bonds provides insight into the bottom-up synthesis of N-heterocycles. This work reports Ni0/Niδ+ synergistic catalysis on the surface of Ni nanoparticles for the highly efficient one-pot formation of C-C/C-N bonds, affording 1,2,3,4-tetrahydroquinoline and its derivatives from 2-amino benzyl alcohol and ethanol without any addition of liquor base or external hydrogen. Ni0/Niδ+ synergistic catalysis has been achieved by regulating the Ni particle size or activating the Ni surface with O2. In the dehydrogenation of -CH2-OH to -CH=O, the formation of C==C and C=N bonds via concurrent cross-condensation, and the transformation of C=C/C=N to C-C/C-N via hydrogen transfer, ethanol dehydrogenation has been found to be the rate-determining step. Reducing the Ni particle size effectively increases the number of surface Niδ+ sites, which accelerates catalytic dehydrogenation through synergistic catalysis between surface Niδ+ and Ni0 sites. The number of surface Niδ+ sites can be further increased by appropriately activating the Ni surface with O2

Substituted Spiroamide Compounds

Substituted spiroamide compounds corresponding to formula (I): wherein A, B, Q1, Q2, Q3, Q4, R1, R8, R9a, R9b, R12, R13, R200 and R210 have defined meanings, processes for their preparation, pharmaceutical compositions containing such compounds, and the use of such compounds for treating or inhibiting pain or other conditions mediated at least in part by the bradykinin 1 receptor (B1R).

SULFONAMIDE DERIVATIVES

The invention is concerned with novel sulfonamide derivatives of formula (I) wherein R1, R2, R3, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.

Novel indolyl derivatives which are L-CPT1 inhibitors

The invention is concerned with novel heterobicyclic derivatives of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, A, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.